npj Breast Cancer

Papers
(The H4-Index of npj Breast Cancer is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
International survey on invasive lobular breast cancer identifies priority research questions341
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers178
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer172
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells158
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?144
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients128
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer102
Biological correlates associated with high-risk breast cancer patients identified using a computational method95
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer93
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment89
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab74
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors70
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women68
Immunotherapy for early triple negative breast cancer: research agenda for the next decade67
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer67
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab65
The clinical and molecular significance associated with STING signaling in breast cancer65
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment59
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models55
Circulating tumor DNA validity and potential uses in metastatic breast cancer54
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays54
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)51
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice51
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer47
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC45
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer44
Survival outcomes after omission of surgery for ductal carcinoma in situ44
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer42
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer42
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer42
Temporal evolution of breast cancer brain metastases treatments and outcomes41
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases40
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis39
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer38
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality38
Is conservative management of ductal carcinoma in situ risky?38
0.061522960662842